Univariate and multivariate Cox regression showed that age, histological grade, PR status, lymph node status, and OFS treatment were independent prognostic factors affecting IDFS in HR+/HER2+ early‐stage premenopausal breast cancer patients treated with trastuzumab (Table 2). Here, ERBB2 is linked to breast carcinoma.